Trial Profile
A Phase 2a, Open-Label Biomarker Study of IC14 for the Treatment of Patients With Rapidly Progressive Amyotrophic Lateral Sclerosis(ALS)
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Atibuclimab (Primary)
- Indications Amyotrophic lateral sclerosis
- Focus Biomarker; Therapeutic Use
- Sponsors Implicit Bioscience
- 12 Mar 2019 Planned End Date changed from 12 Jul 2020 to 12 Jul 2021.
- 12 Mar 2019 Planned primary completion date changed from 12 Apr 2020 to 12 Apr 2021.
- 12 Mar 2019 Planned initiation date changed from 1 Sep 2018 to 1 Sep 2019.